Omnitura 2500 iStock_000019408736_Large.jpg
Omnitura 2500 iStock_000050664932_Large copy.jpg
Omnitura Blue Green Molecule 2500.jpeg
Omnitura 2500 iStock_000019408736_Large.jpg

WE ARE OMNITURA


Omnitura Therapeutics is a biopharmaceutical company commercializing a new class of multivalent immuno-oncology (I-O) therapy designed to address the complex and heterogeneous nature of cancer.

SCROLL DOWN

WE ARE OMNITURA


Omnitura Therapeutics is a biopharmaceutical company commercializing a new class of multivalent immuno-oncology (I-O) therapy designed to address the complex and heterogeneous nature of cancer.

MULTIVALENT; The key to next generation cancer treatment

We are focused on developing multivalent immuno-oncology drugs capable of regulating, not blocking, multiple molecular pathways, in order to kill different cancer cell sub-types as well as reboot the immune system, all while providing patients with good quality of life. Our lead drug candidate Aneustat™ represents an ideal non-toxic therapy for cancer.

- Jeff Dao, Co-CEO, Omnitura

Omnitura 2500 iStock_000050664932_Large copy.jpg

OUR MISSION


Omnitura's vision is to make cancer a manageable chronic disease - a disease we live with, while enjoying good quality life, rather than die from. It is envisioned that the Omnitura solution may ultimately reduce the incidence of cancer.

SCROLL DOWN

OUR MISSION


Omnitura's vision is to make cancer a manageable chronic disease - a disease we live with, while enjoying good quality life, rather than die from. It is envisioned that the Omnitura solution may ultimately reduce the incidence of cancer.

 

A PARADIGM SHIFT IS HAPPENING

The next generation of cancer drug development will be capable of disrupting numerous molecular pathways associated with cancer, all while empowering the body's own immune systemOmnitura is positioned to be a leader in this new multivalent drug development paradigm. It all starts with Aneustat™.

Omnitura Blue Green Molecule 2500.jpeg

INTRODUCING ANEUSTAT™


Aneustat™ is a non-toxic, multivalent immuno-oncology drug candidate designed to intercept, treat and prevent cancer. Aneustat™ has successfully completed phase I/IIa clinical trials and is now entering phase II clinical trials for prostate cancer.

SCROLL DOWN

INTRODUCING ANEUSTAT™


Aneustat™ is a non-toxic, multivalent immuno-oncology drug candidate designed to intercept, treat and prevent cancer. Aneustat™ has successfully completed phase I/IIa clinical trials and is now entering phase II clinical trials for prostate cancer.